Global office locator

As RBQM adoption grows, sponsors are rethinking how monitoring resources, data and expertise are deployed across studies. In this article for BioPharm International, Helen Yeardley explores why effective capacity planni...

Support, development and flexibility can make a real difference throughout a CRA career. For Eunyong, CRA II in Germany, joining ICON has given her the opportunity to build confidence through structured onboarding, in f...

Earlier this month, colleagues from ICON took on the Mexico City Marathon, embracing one of the city’s most demanding sporting challenges with determination, preparation and team spirit. For each runner, the experience ...

Packaging is no longer just a product consideration. Under the PPWR, it has become a strategic regulatory priority for pharma and medtech companies marketing in the EU. ICON’s SMEs outline how businesses can prepare for...

Recognition as one of TIME’s World’s Most Sustainable Companies 2026 highlights the strength of our ESG strategy in action. From global operations to local impact, we are committed to embedding sustainable practices acr...

Hear the latest updates and insights on clinical trial operations from the Accellacare team of professionals at the #GSSS this October 15-18. Meet us at the Signia by Hilton Orlando Bonnet Creek, booth \#406. https://ow....

Multiple authors or key contributors? No problem. PubsHub PMSolution makes it easy for your team to collaborate more efficiently. Secure and compliant, you can maintain automate workflows, maintain version control, and u...

Career growth can look different for everyone. A good reminder from Yazmin García, Manager, Medical Affairs in Mexico, to focus on your own development, keep learning and give yourself time to grow. At ICON, we believe...

Emerging approaches to first-in-human studies are helping sponsors obtain meaningful clinical insights sooner through integrated study designs, stronger patient engagement, and strategic biomarker implementation. In thi...

EHDS represents a major milestone in European health data governance. Learn how CROs are evolving from data custodians to regulated data users, and what this means for the future of real-world evidence generation. Read...

As AI adoption accelerates across healthcare, ensuring transparency, reproducibility, and scientific rigour remains essential. ICON discusses how organisations can apply AI and machine learning to real-world oncology dat...

Because patients can’t wait, every rare disease development decision matters. Meet ICON at World Orphan Drug Congress Europe, booth \#313, to discuss how our integrated development and regulatory strategy, patient advoca...